Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2014; 20(34): 12330-12340
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12330
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12330
Efficacy of immunosuppression monotherapy after liver transplantation: A meta-analysis
Xiang Lan, Meng-Gang Liu, Hong-Xu Chen, Hong-Ming Liu, Wei Zeng, Dong Wei, Ping Chen, Department of Hepatobiliary Surgery, Daping Hospital, the Third Military Medical University, Chongqing 400042, China
Author contributions: Lan X and Liu MG contributed equally to this study; all authors contributed to the manuscript.
Correspondence to: Dr. Ping Chen, Department of Hepatobiliary Surgery, Daping Hospital, the Third Military Medical University, 10 Changjiang Branch Road, Daping, Chongqing 400042, China. chenping10701@hotmail.com
Telephone: +86-23-68757966 Fax: +86-23-68757966
Received: January 1, 2014
Revised: February 17, 2014
Accepted: April 28, 2014
Published online: September 14, 2014
Revised: February 17, 2014
Accepted: April 28, 2014
Published online: September 14, 2014
Core Tip
Core tip: Immunosuppression is used to reduce rejection after liver transplantation. There is considerable controversy regarding whether an immunosuppression monotherapy should be used after transplantation. To assess the advantages (lower adverse events such as hypertension) and disadvantages (more episodes of rejection) of immunosuppression monotherapy after transplantation. To assess the impact of immunosuppression monotherapy on recurrence of hepatitis C.